Dong-A Socio Holdings Co., Ltd. (000640.KS)
KRW 110000.0
(4.86%)
KRW 110000.0
(4.86%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 929.79 Billion KRW | 26.88% |
| 2022 | 732.79 Billion KRW | 3.74% |
| 2021 | 706.34 Billion KRW | 13.49% |
| 2020 | 622.38 Billion KRW | 1.75% |
| 2019 | 611.67 Billion KRW | 20.84% |
| 2018 | 506.16 Billion KRW | -7.16% |
| 2017 | 545.19 Billion KRW | 3.58% |
| 2016 | 526.35 Billion KRW | -15.22% |
| 2015 | 620.87 Billion KRW | 13.59% |
| 2014 | 546.59 Billion KRW | 15.39% |
| 2013 | 473.67 Billion KRW | -43.74% |
| 2012 | 841.86 Billion KRW | 33.45% |
| 2011 | 630.84 Billion KRW | 29.1% |
| 2010 | 488.66 Billion KRW | 2.46% |
| 2009 | 476.92 Billion KRW | 13.82% |
| 2008 | 419 Billion KRW | 8.82% |
| 2007 | 385.02 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 990.13 Billion KRW | 3.56% |
| 2024 Q1 | 956.13 Billion KRW | 2.83% |
| 2023 FY | 929.79 Billion KRW | 26.88% |
| 2023 Q2 | 857.54 Billion KRW | -1.38% |
| 2023 Q1 | 869.52 Billion KRW | 18.66% |
| 2023 Q3 | 918.62 Billion KRW | 7.12% |
| 2023 Q4 | 929.79 Billion KRW | 1.22% |
| 2022 Q4 | 732.79 Billion KRW | 0.36% |
| 2022 FY | 732.79 Billion KRW | 3.74% |
| 2022 Q3 | 730.18 Billion KRW | -0.64% |
| 2022 Q2 | 734.91 Billion KRW | 1.17% |
| 2022 Q1 | 726.41 Billion KRW | 2.84% |
| 2021 Q4 | 706.34 Billion KRW | -3.89% |
| 2021 FY | 706.34 Billion KRW | 13.49% |
| 2021 Q3 | 734.93 Billion KRW | 11.39% |
| 2021 Q2 | 659.79 Billion KRW | 3.13% |
| 2021 Q1 | 639.76 Billion KRW | 2.79% |
| 2020 Q3 | 625.89 Billion KRW | -0.44% |
| 2020 Q1 | 588.37 Billion KRW | -3.81% |
| 2020 Q2 | 628.68 Billion KRW | 6.85% |
| 2020 Q4 | 622.38 Billion KRW | -0.56% |
| 2020 FY | 622.38 Billion KRW | 1.75% |
| 2019 Q3 | 583.85 Billion KRW | -4.33% |
| 2019 Q4 | 611.67 Billion KRW | 4.76% |
| 2019 Q2 | 610.29 Billion KRW | 1.45% |
| 2019 Q1 | 601.57 Billion KRW | 18.85% |
| 2019 FY | 611.67 Billion KRW | 20.84% |
| 2018 Q4 | 506.16 Billion KRW | -5.4% |
| 2018 FY | 506.16 Billion KRW | -7.16% |
| 2018 Q2 | 543.07 Billion KRW | -0.93% |
| 2018 Q1 | 548.17 Billion KRW | 0.55% |
| 2018 Q3 | 535.04 Billion KRW | -1.48% |
| 2017 Q4 | 545.19 Billion KRW | -4.14% |
| 2017 Q3 | 568.72 Billion KRW | -4.71% |
| 2017 Q2 | 596.81 Billion KRW | -4.02% |
| 2017 FY | 545.19 Billion KRW | 3.58% |
| 2017 Q1 | 621.81 Billion KRW | 18.14% |
| 2016 FY | 526.35 Billion KRW | -15.22% |
| 2016 Q2 | 519.95 Billion KRW | -15.7% |
| 2016 Q3 | 518.42 Billion KRW | -0.29% |
| 2016 Q4 | 526.35 Billion KRW | 1.53% |
| 2016 Q1 | 616.76 Billion KRW | -0.66% |
| 2015 Q4 | 620.87 Billion KRW | -0.21% |
| 2015 Q3 | 622.18 Billion KRW | -1.47% |
| 2015 FY | 620.87 Billion KRW | 13.59% |
| 2015 Q1 | 575.89 Billion KRW | 5.36% |
| 2015 Q2 | 631.48 Billion KRW | 9.65% |
| 2014 Q3 | 564.97 Billion KRW | 2.4% |
| 2014 FY | 546.59 Billion KRW | 15.39% |
| 2014 Q4 | 546.59 Billion KRW | -3.25% |
| 2014 Q2 | 551.72 Billion KRW | 11.04% |
| 2014 Q1 | 496.86 Billion KRW | 4.9% |
| 2013 Q2 | 425.41 Billion KRW | 4.19% |
| 2013 Q3 | 469.5 Billion KRW | 10.36% |
| 2013 FY | 473.67 Billion KRW | -43.74% |
| 2013 Q4 | 473.67 Billion KRW | 0.89% |
| 2013 Q1 | 408.31 Billion KRW | -51.5% |
| 2012 Q1 | 546.27 Billion KRW | 0.0% |
| 2012 Q4 | 841.86 Billion KRW | 0.0% |
| 2012 FY | 841.86 Billion KRW | 33.45% |
| 2011 Q2 | 439.43 Billion KRW | -2.02% |
| 2011 FY | 630.84 Billion KRW | 29.1% |
| 2011 Q1 | 448.5 Billion KRW | 0.0% |
| 2011 Q3 | 462.24 Billion KRW | 5.19% |
| 2010 Q3 | 447.25 Billion KRW | -5.72% |
| 2010 Q1 | 440.46 Billion KRW | 0.0% |
| 2010 Q2 | 474.36 Billion KRW | 7.7% |
| 2010 FY | 488.66 Billion KRW | 2.46% |
| 2009 Q1 | 429.56 Billion KRW | 0.0% |
| 2009 Q2 | 422.22 Billion KRW | -1.71% |
| 2009 FY | 476.92 Billion KRW | 13.82% |
| 2009 Q3 | 422.61 Billion KRW | 0.09% |
| 2008 Q3 | 382.63 Billion KRW | 7.43% |
| 2008 Q1 | 355.31 Billion KRW | 0.0% |
| 2008 Q2 | 356.16 Billion KRW | 0.24% |
| 2008 FY | 419 Billion KRW | 8.82% |
| 2007 Q1 | 339.82 Billion KRW | 0.0% |
| 2007 Q2 | 331.93 Billion KRW | -2.32% |
| 2007 Q3 | 402.29 Billion KRW | 21.2% |
| 2007 FY | 385.02 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -1094.224% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | -31.495% |
| HANDOK Inc. | 449.7 Billion KRW | -106.756% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -985.32% |
| Yuhan Corporation | 712.33 Billion KRW | -30.528% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | -47.14% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -5749.809% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | -9.154% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -1637.009% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -351.631% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -1136.91% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -529.116% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -1220.71% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -1094.224% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -2451.846% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -270.214% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -321.285% |
| JW Holdings Corporation | 827.51 Billion KRW | -12.361% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | -112.771% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | -58.454% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -144.942% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -1072.484% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -1228.896% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -282.865% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -181.506% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -1094.224% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | -89.747% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | -8.364% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -144.942% |
| Yuhan Corporation | 712.33 Billion KRW | -30.528% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | -94.595% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -578.84% |
| Suheung Co., Ltd. | 516.66 Billion KRW | -79.96% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -144.942% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -501.669% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -933.506% |
| CKD Bio Corp. | 170.76 Billion KRW | -444.503% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -281.48% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -489.76% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -2061.356% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -1072.484% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | -46.999% |
| Boryung Corporation | 373.1 Billion KRW | -149.203% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -346.594% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -351.631% |
| JW Lifescience Corporation | 96.44 Billion KRW | -864.087% |